Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zivo Bioscience, Inc.ZIVO · Entity 9611 | Director | January 01, 2025 | January 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zivo Bioscience, Inc.
Report date January 01, 2025 · Filed January 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 130,906 |
Ending reported balance
After 2025-01-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-01-01 · Grant · Acquired 1,354 · Balance 123,378 Row 2 · 2025-01-01 · Grant · Acquired 7,528 · Balance 130,906 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
REPROS THERAPEUTICS INC.
Report date January 29, 2018 · Filed January 31, 2018
Section 16 reporting ended · disclosed 2018-01-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-01-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-01-29 · Other · Disposed 12,221 · Balance 27,779 Row 2 · 2018-01-31 · Disposition to issuer · Disposed 27,779 · Balance 0 F1: Consists of restricted stock units. Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated December 11, 2018, by and among Repros Therapeutics Inc. (the "Issuer"), Allergan Sales, LLC ("Parent") and Celestial Merger Sub, Inc. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each outstanding restricted stock unit and any associated rights to the issuance of shares of the Issuer's common stock, par value $0.001 per share (the "Shares") upon the achievement of Issuer performance goals (the "Issuer RSUs") under the Issuer's equity plans that was not then vested was cancelled, (continued in Footnote 2) F2: (continued from Footnote 1) and the holder of such cancelled Issuer RSUs became entitled to receive, in exchange therefor, an amount in cash equal to the product of (x) the total number of Shares subject to (or deliverable under) such Issuer RSUs immediately prior to the effective time of the Merger (the "Effective Time") (determined after giving effect to the accelerated vesting and deemed achievement at maximum applicable performance levels) multiplied by (y) $0.67 in cash (the "Closing Amount"). These restricted stock units were fully vested immediately prior to the Effective Time. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.32 · Expires 2027-09-15 | Direct | 0 |
Reported balance
After 2018-01-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-01-31 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to purchase Shares (a "Company Option") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than the Closing Amount (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled at the Effective Time without any consideration payable therefor. F4: The Shares subject to this option were fully vested immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units. Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated December 11, 2018, by and among Repros Therapeutics Inc. (the "Issuer"), Allergan Sales, LLC ("Parent") and Celestial Merger Sub, Inc. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each outstanding restricted stock unit and any associated rights to the issuance of shares of the Issuer's common stock, par value $0.001 per share (the "Shares") upon the achievement of Issuer performance goals (the "Issuer RSUs") under the Issuer's equity plans that was not then vested was cancelled, (continued in Footnote 2)
F2: (continued from Footnote 1) and the holder of such cancelled Issuer RSUs became entitled to receive, in exchange therefor, an amount in cash equal to the product of (x) the total number of Shares subject to (or deliverable under) such Issuer RSUs immediately prior to the effective time of the Merger (the "Effective Time") (determined after giving effect to the accelerated vesting and deemed achievement at maximum applicable performance levels) multiplied by (y) $0.67 in cash (the "Closing Amount"). These restricted stock units were fully vested immediately prior to the Effective Time.
F3: Pursuant to the terms of the Merger Agreement, each option to purchase Shares (a "Company Option") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than the Closing Amount (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled at the Effective Time without any consideration payable therefor.
F4: The Shares subject to this option were fully vested immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2025 Filed Jan 3, 2025 21:25 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantCommon Stock | 7,528 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-25-000103 · section16.xml · nonDerivative · entry 2 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,906 Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:25 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantCommon Stock | 1,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-25-000103 · section16.xml · nonDerivative · entry 1 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,378 Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:36 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantCommon Stock | 6,273 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-24-007744 · section16.xml · nonDerivative · entry 1 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,024 F1 · balance_after: The reporting person's previous Form 4 filed on June 6, 2024 inadvertently included an additional 66 shares of common stock in the total securities beneficially owned, which has been corrected in this Form 4. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:28 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Disposition to issuerNonstatutory Stock Option to Purchase Common Stock · Derivative | 3,626 | Not disclosed Strike: $16.74 | Not disclosed |
DisclosureSEC source: 0001654954-24-007463 · section16.xml · derivative · entry 7 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,626 shares Expires 2033-06-11 F1 · derivative.exercise_price: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F1 · shares: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F3 · price: The Issuer canceled options for an aggregate 13,200 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 30,010 shares of restricted stock. F4 · derivative.exercise_date: The canceled option was issued pursuant to the 2021 Equity Incentive Plan on 6/12/2023 and vests as follows: 25% on the first three 3-month anniversaries of the grant, and 25% on the day prior to the Company's 2024 Annual Meeting of Stockholders, subject to the reporting person's continuous service on each applicable vesting date. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:28 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Disposition to issuerNonstatutory Stock Option to Purchase Common Stock · Derivative | 707 | Not disclosed Strike: $17.16 | Not disclosed |
DisclosureSEC source: 0001654954-24-007463 · section16.xml · derivative · entry 6 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 707 shares Expires 2032-12-15 F1 · derivative.exercise_price: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F1 · shares: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F3 · price: The Issuer canceled options for an aggregate 13,200 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 30,010 shares of restricted stock. F2 · derivative.exercise_date: The canceled options were fully vested. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:28 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Disposition to issuerNonstatutory Stock Option to Purchase Common Stock · Derivative | 2,632 | Not disclosed Strike: $21.66 | Not disclosed |
DisclosureSEC source: 0001654954-24-007463 · section16.xml · derivative · entry 5 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,632 shares Expires 2032-07-27 F1 · derivative.exercise_price: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F1 · shares: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F3 · price: The Issuer canceled options for an aggregate 13,200 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 30,010 shares of restricted stock. F2 · derivative.exercise_date: The canceled options were fully vested. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:28 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Disposition to issuerNonstatutory Stock Option to Purchase Common Stock · Derivative | 4,333 | Not disclosed Strike: $33.00 | Not disclosed |
DisclosureSEC source: 0001654954-24-007463 · section16.xml · derivative · entry 4 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,333 shares Expires 2031-10-20 F1 · derivative.exercise_price: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F1 · shares: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F3 · price: The Issuer canceled options for an aggregate 13,200 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 30,010 shares of restricted stock. F2 · derivative.exercise_date: The canceled options were fully vested. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:28 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Disposition to issuerNonstatutory Stock Option to Purchase Common Stock · Derivative | 1,902 | Not disclosed Strike: $26.88 | Not disclosed |
DisclosureSEC source: 0001654954-24-007463 · section16.xml · derivative · entry 3 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,902 shares Expires 2031-10-11 F1 · derivative.exercise_price: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F1 · shares: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023. F3 · price: The Issuer canceled options for an aggregate 13,200 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 30,010 shares of restricted stock. F2 · derivative.exercise_date: The canceled options were fully vested. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:28 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantCommon Stock | 84,941 | $7.96 | $676,130.36 |
DisclosureSEC source: 0001654954-24-007463 · section16.xml · nonDerivative · entry 2 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,817 Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:28 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantCommon Stock | 30,010 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-24-007463 · section16.xml · nonDerivative · entry 1 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,876 F3 · price: The Issuer canceled options for an aggregate 13,200 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 30,010 shares of restricted stock. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 21:05 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantNonstatutory Stock Option to Purchase Common Stock · Derivative | 21,756 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001654954-23-008022 · section16.xml · derivative · entry 1 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,756 Underlying: Common Stock · 21,756 shares Expires 2033-06-11 F1 · derivative.exercise_date: The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 25% on the first three 3-month anniversaries of the grant, and 25% on the day prior to the Company's 2024 Annual Meeting of Stockholders, subject to the reporting person's continuous service on each applicable vesting date. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:39 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 300 | $2.64 | $792.00 |
DisclosureSEC source: 0001654954-22-016814 · section16.xml · nonDerivative · entry 1 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,198 Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 21:15 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantNonstatutory Stock Option to Purchase Common Stock · Derivative | 4,244 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001654954-22-016733 · section16.xml · derivative · entry 1 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,244 Underlying: Common Stock · 4,244 shares Expires 2032-12-15 F1 · derivative.exercise_date: The option was issued pursuant to the 2021 Equity Incentive Plan and vested immediately upon grant. Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 20:22 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantNonstatutory Stock Option to Purchase Common Stock · Derivative | 15,797 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001654954-22-010396 · section16.xml · derivative · entry 1 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,797 Underlying: Common Stock · 15,797 shares Expires 2032-07-27 F1 · derivative.exercise_date: The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 25% on the first three 3-month anniversaries of the grant, and 25% on the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the reporting person's continuous service on each applicable vesting date. Read SEC document |
| July 28, 2022 Filed Dec 8, 2022 21:18 UTC Amendment | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantNonstatutory Stock Option to Purchase Common Stock · Derivative | 15,797 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001654954-22-016254 · section16.xml · derivative · entry 1 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,797 Underlying: Common Stock · 15,797 shares Expires 2032-07-27 F1 · security: This amendment is being filed solely to correct the date of the earliest transaction reported to July 28, 2022. F2 · derivative.exercise_date: The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 25% on the first three 3-month anniversaries of the grant, and 25% on the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the reporting person's continuous service on each applicable vesting date. Read SEC document |
| October 21, 2021 Filed Oct 25, 2021 23:01 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantNonstatutory Stock Option to Purchase Common Stock · Derivative | 26,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001654954-21-011335 · section16.xml · derivative · entry 1 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2031-10-20 F1 · derivative.exercise_date: The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 25% upon acceptance of the grant, 25% on each of the next two 4-month anniversaries of the grant, and 25% on the day prior to the Company's 2022 Annual Meeting of Stockholders. Read SEC document |
| October 12, 2021 Filed Oct 16, 2021 01:18 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantNonstatutory Stock Option to Purchase Common Stock · Derivative | 11,416 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0001654954-21-011168 · section16.xml · derivative · entry 1 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,416 Underlying: Common Stock · 11,416 shares Expires 2031-10-11 F1 · derivative.exercise_date: The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 25% on the first three 3-month anniversaries of the grant, and 25% on the day prior to the Company's 2022 Annual General Meeting of Stockholders, subject to the reporting person's continuous service on each applicable vesting date. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 19:53 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock Purchase Warrant · Derivative | 400 | $0.01 Strike: $5.50 | $4.00 |
DisclosureSEC source: 0001078782-21-000536 · primary_doc.xml · derivative · entry 2 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 Underlying: Common Stock · 400 shares Expires 2026-06-02 Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 19:53 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | PurchaseCommon Stock | 400 | $4.99 | $1,996.00 |
DisclosureSEC source: 0001078782-21-000536 · primary_doc.xml · nonDerivative · entry 1 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,898 F1 · balance_after: The share amount has been adjusted to reflect the reverse stock split effective on May 28, 2021 whereby each eighty shares of common stock issued and outstanding prior to the split were combined and converted into one share of common stock. Read SEC document |
| September 30, 2020 Filed Dec 1, 2020 23:17 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Tax withholdingCommon Stock Purchase Warrant · Derivative | 500,000 | Not disclosed Strike: $0.12 | Not disclosed |
DisclosureSEC source: 0001078782-20-000933 · primary_doc.xml · derivative · entry 4 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2025-09-30 F1 · price: The warrants were issued to the reporting person as compensation for acting as a director. Read SEC document |
| August 18, 2020 Filed Dec 1, 2020 23:17 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Exercise / conversionCommon Stock Purchase Warrant · Derivative | 250,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001078782-20-000933 · primary_doc.xml · derivative · entry 3 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2020-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Dec 1, 2020 23:17 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Tax withholdingCommon Stock | 208,333 | $0.12 | $24,999.96 |
DisclosureSEC source: 0001078782-20-000933 · primary_doc.xml · nonDerivative · entry 2 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,849 Read SEC document |
| August 18, 2020 Filed Dec 1, 2020 23:17 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Exercise / conversionCommon Stock | 250,000 | $0.10 | $25,000.00 |
DisclosureSEC source: 0001078782-20-000933 · primary_doc.xml · nonDerivative · entry 1 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,182 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2020 Filed Apr 24, 2020 15:56 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Exercise / conversionCommon Stock Purchase Warrant · Derivative | 500,000 | Not disclosed Strike: $0.07 | Not disclosed |
DisclosureSEC source: 0001078782-20-000283 · primary_doc.xml · derivative · entry 9 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2022-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The warrants were exercised utilizing the "cashless" exercise feature. Read SEC document |
| April 15, 2020 Filed Apr 24, 2020 15:56 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Exercise / conversionCommon Stock Purchase Warrant · Derivative | 250,000 | Not disclosed Strike: $0.05 | Not disclosed |
DisclosureSEC source: 0001078782-20-000283 · primary_doc.xml · derivative · entry 8 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2021-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The warrants were exercised utilizing the "cashless" exercise feature. Read SEC document |
| April 15, 2020 Filed Apr 24, 2020 15:56 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Exercise / conversionCommon Stock | 181,818 | $0.07 | $12,727.26 |
DisclosureSEC source: 0001078782-20-000283 · primary_doc.xml · nonDerivative · entry 2 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,182 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2020 Filed Apr 24, 2020 15:56 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Exercise / conversionCommon Stock | 136,364 | $0.05 | $6,818.20 |
DisclosureSEC source: 0001078782-20-000283 · primary_doc.xml · nonDerivative · entry 1 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2019 Filed Apr 24, 2020 15:56 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantCommon Stock Purchase Warrant · Derivative | 500,000 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0001078782-20-000283 · primary_doc.xml · derivative · entry 7 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2024-09-26 F1 · price: The warrants were issued to the reporting person as compensation for acting as a director. Read SEC document |
| September 28, 2018 Filed Apr 24, 2020 15:56 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantCommon Stock Purchase Warrant · Derivative | 500,000 | Not disclosed Strike: $0.14 | Not disclosed |
DisclosureSEC source: 0001078782-20-000283 · primary_doc.xml · derivative · entry 6 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2023-09-26 F1 · price: The warrants were issued to the reporting person as compensation for acting as a director. Read SEC document |
| January 31, 2018 Filed Jan 31, 2018 09:59 UTC | REPROS THERAPEUTICS INC. RPRX · Entity 169957 | Disposition to issuerStock Option · Derivative | 5,000 | Not disclosed Strike: $0.32 | Not disclosed |
DisclosureSEC source: 0001144204-18-004781 · tv484342_4.xml · derivative · entry 3 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2027-09-15 F3 · price: Pursuant to the terms of the Merger Agreement, each option to purchase Shares (a "Company Option") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than the Closing Amount (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled at the Effective Time without any consideration payable therefor. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to purchase Shares (a "Company Option") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than the Closing Amount (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled at the Effective Time without any consideration payable therefor. F4 · derivative.exercise_date: The Shares subject to this option were fully vested immediately prior to the Effective Time. Read SEC document |
| January 31, 2018 Filed Jan 31, 2018 09:59 UTC | REPROS THERAPEUTICS INC. RPRX · Entity 169957 | Disposition to issuerCommon Stock | 27,779 | $0.67 | $18,611.93 |
DisclosureSEC source: 0001144204-18-004781 · tv484342_4.xml · nonDerivative · entry 2 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Consists of restricted stock units. Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated December 11, 2018, by and among Repros Therapeutics Inc. (the "Issuer"), Allergan Sales, LLC ("Parent") and Celestial Merger Sub, Inc. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each outstanding restricted stock unit and any associated rights to the issuance of shares of the Issuer's common stock, par value $0.001 per share (the "Shares") upon the achievement of Issuer performance goals (the "Issuer RSUs") under the Issuer's equity plans that was not then vested was cancelled, (continued in Footnote 2) F2 · price: (continued from Footnote 1) and the holder of such cancelled Issuer RSUs became entitled to receive, in exchange therefor, an amount in cash equal to the product of (x) the total number of Shares subject to (or deliverable under) such Issuer RSUs immediately prior to the effective time of the Merger (the "Effective Time") (determined after giving effect to the accelerated vesting and deemed achievement at maximum applicable performance levels) multiplied by (y) $0.67 in cash (the "Closing Amount"). These restricted stock units were fully vested immediately prior to the Effective Time. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 09:59 UTC | REPROS THERAPEUTICS INC. RPRX · Entity 169957 | OtherCommon Stock | 12,221 | $0.67 | $8,188.07 |
DisclosureSEC source: 0001144204-18-004781 · tv484342_4.xml · nonDerivative · entry 1 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,779 Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 16:02 UTC | REPROS THERAPEUTICS INC. RPRX · Entity 169957 | GrantStock Option · Derivative | 5,000 | Not disclosed Strike: $0.32 | Not disclosed |
DisclosureSEC source: 0001144204-17-048489 · v475367_4.xml · derivative · entry 1 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common · 5,000 shares Expires 2027-09-15 F2 · price: Received as compensation for service on Board of Directors of issuer. F1 · derivative.exercise_date: Option shares shall vest in equal monthly installments over the first twelve months after the date of grant. Read SEC document |
| September 11, 2017 Filed Apr 24, 2020 15:56 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantCommon Stock Purchase Warrant · Derivative | 500,000 | Not disclosed Strike: $0.07 | Not disclosed |
DisclosureSEC source: 0001078782-20-000283 · primary_doc.xml · derivative · entry 5 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2022-09-11 F1 · price: The warrants were issued to the reporting person as compensation for acting as a director. Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 16:28 UTC | REPROS THERAPEUTICS INC. RPRX · Entity 169957 | GrantCommon Stock | 40,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-17-009366 · v459723_4.xml · nonDerivative · entry 1 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · price: Consists of Restricted Stock Units (RSUs), representing the right to receive one share of the issuer's common stock for each vested RSU, that were awarded on February 13, 2017 as compensation to non-employee members of the Board of Directors. The RSUs shall vest in thirty-six (36) equal increments on the last day of each calendar month from February 2017 through January 2020. Read SEC document |
| November 21, 2016 Filed Nov 23, 2016 16:07 UTC | REPROS THERAPEUTICS INC. RPRX · Entity 169957 | SaleCommon Stock | 3,305 | $1.95 | $6,444.75 |
DisclosureSEC source: 0001144204-16-136348 · v453807_4.xml · nonDerivative · entry 1 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| September 10, 2016 Filed Apr 24, 2020 15:56 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantCommon Stock Purchase Warrant · Derivative | 250,000 | Not disclosed Strike: $0.05 | Not disclosed |
DisclosureSEC source: 0001078782-20-000283 · primary_doc.xml · derivative · entry 4 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2021-09-10 F1 · price: The warrants were issued to the reporting person as compensation for acting as a director. Read SEC document |
| September 10, 2015 Filed Apr 24, 2020 15:56 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantCommon Stock Purchase Warrant · Derivative | 250,000 | Not disclosed Strike: $0.10 | Not disclosed |
DisclosureSEC source: 0001078782-20-000283 · primary_doc.xml · derivative · entry 3 Masterson Nola E · CIK 0001305231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2020-09-10 F1 · price: The warrants were issued to the reporting person as compensation for acting as a director. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.